Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Income from Continuing Operations: 2021-2025

Historic Income from Continuing Operations for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $18.4 million.

  • Kiniksa Pharmaceuticals International's Income from Continuing Operations rose 245.24% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.9 million, marking a year-over-year increase of 142.99%. This contributed to the annual value of -$43.2 million for FY2024, which is 28.48% up from last year.
  • Kiniksa Pharmaceuticals International's Income from Continuing Operations amounted to $18.4 million in Q3 2025, which was up 3.38% from $17.8 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's 5-year Income from Continuing Operations high stood at $224.1 million for Q3 2022, and its period low was -$49.5 million during Q1 2021.
  • Moreover, its 3-year median value for Income from Continuing Operations was -$8.9 million (2024), whereas its average is -$5.3 million.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first skyrocketed by 833.67% in 2022, then crashed by 155.63% in 2023.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Income from Continuing Operations (Quarterly) stood at -$44.1 million in 2021, then skyrocketed by 300.84% to $88.5 million in 2022, then slumped by 155.63% to -$49.2 million in 2023, then skyrocketed by 81.95% to -$8.9 million in 2024, then spiked by 245.24% to $18.4 million in 2025.
  • Its Income from Continuing Operations was $18.4 million in Q3 2025, compared to $17.8 million in Q2 2025 and $8.5 million in Q1 2025.